Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Significant Growth in Short Interest

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 199,800 shares, an increase of 25.2% from the March 15th total of 159,600 shares. Approximately 26.1% of the company’s stock are sold short. Based on an average trading volume of 3,420,000 shares, the days-to-cover ratio is currently 0.1 days.

Hepion Pharmaceuticals Stock Down 6.1 %

Shares of HEPA stock traded down $0.02 during trading on Friday, reaching $0.32. The company’s stock had a trading volume of 1,232,914 shares, compared to its average volume of 1,027,787. Hepion Pharmaceuticals has a one year low of $0.31 and a one year high of $79.98. The business has a fifty day moving average price of $3.26 and a 200-day moving average price of $18.46. The company has a market cap of $3.54 million, a price-to-earnings ratio of -0.07 and a beta of 1.79.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.